◀ Back to MAP2K1

JAK1 — MAP2K1

Pathways - manually collected, often from reviews:

• NCI Pathway Database IL2-mediated signaling events: IL2/IL2R alpha/beta/gamma/JAK1/LCK/JAK3 complex (IL2RA-IL2RB-IL2RG-IL2-JAK1-LCK-JAK3) → MEK1-2 (MAP2K1/MAP2K2) (modification, activates) Delespine-Carmagnat et al., Eur J Immunol 2000, Fung et al., Cell Signal 2003, Nielsen et al., Eur J Immunol 1994, Frank et al., Proc Natl Acad Sci U S A 1995, Johnston et al., Proc Natl Acad Sci U S A 1995, Hou et al., Immunity 1995, Lin et al., Immunity 1995, Ng et al., J Biol Chem 1997
  Evidence: mutant phenotype, assay, physical interaction

Text-mined interactions from Literome

Booz et al., Mol Cell Biochem 2002 : This effect of endothelin-1 on LIFalpha and Jak1 was attenuated by the MEK1 inhibitor, PD98059, implicating involvement of the ERK kinases
Chang et al., Gen Comp Endocrinol 2012 : The specific inhibitors of either MEK1 ( U-0126 and PD-98059 ), JAK ( AG-490 ), JNK ( SP-600125 ), or PI3K ( LY-294002 and wortmannin ) reduced ET-1 increased levels of SOCS-3 mRNA and respectively inhibited ET-1 stimulated activities of MEK1 , JAK, JNK, and PI3K